Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$40.20 +0.4%	$37.37	$16.50 ▼ $43.58	$3.74B	N/A	42,066 shs	1,807 shs
HCM HUTCHMED	$15.45 -0.2%	$16.44	$11.51 ▼ $21.50	$2.69B	0.55	83,616 shs	46,732 shs
NRIX Nurix Therapeutics	$9.80 +1.6%	$11.81	$8.18 ▼ $29.56	$749.59M	2.14	872,577 shs	349,726 shs
PTGX Protagonist Therapeutics	$54.38 +1.2%	$53.88	$33.31 ▼ $60.60	$3.39B	2.33	942,928 shs	222,353 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-4.55%	+6.49%	+4.71%	+66.56%	+4,003,999,900.00%
HCM HUTCHMED	+3.20%	-10.42%	-3.49%	+17.81%	-22.09%
NRIX Nurix Therapeutics	-1.93%	-14.45%	-22.43%	-0.82%	-53.65%
PTGX Protagonist Therapeutics	+5.25%	-0.15%	+1.42%	+21.41%	+38.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	3.1618 of 5 stars	3.3	4.0	0.0	0.0	2.9	0.0	1.9
NRIX Nurix Therapeutics	1.649 of 5 stars	4.4	1.0	0.0	0.0	0.0	0.8	0.0
PTGX Protagonist Therapeutics	1.92 of 5 stars	2.5	3.0	0.0	0.0	3.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
HCM HUTCHMED	2.50	Moderate Buy	$28.00	81.29% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	194.56% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	23.59% Upside

Current Analyst Ratings Breakdown

Latest NRIX, PTGX, AAPG, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	27.82	N/A	N/A	$0.48 per share	83.75
HCM HUTCHMED	$630.20M	4.27	$0.30 per share	52.22	$4.43 per share	3.49
NRIX Nurix Therapeutics	$54.55M	13.73	N/A	N/A	$7.44 per share	1.32
PTGX Protagonist Therapeutics	$434.43M	7.79	$4.81 per share	11.31	$11.33 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	$37.73M	N/A	0.00	10.58	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.70	77.75	N/A	N/A	24.88%	8.12%	7.41%	N/A

Latest NRIX, PTGX, AAPG, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
HCM HUTCHMED	0.05	4.65	4.51
NRIX Nurix Therapeutics	N/A	6.82	6.82
PTGX Protagonist Therapeutics	N/A	16.97	16.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
HCM HUTCHMED	8.82%
NRIX Nurix Therapeutics	N/A
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
HCM HUTCHMED	3.60%
NRIX Nurix Therapeutics	7.40%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	92.96 million	N/A	N/A
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable

NRIX, PTGX, AAPG, and HCM Headlines

Recent News About These Companies

Knott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 12 at 8:17 AM | marketbeat.com

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?

August 12 at 5:49 AM | finance.yahoo.com

Wedbush Issues Optimistic Estimate for PTGX Earnings

August 12 at 2:45 AM | americanbankingnews.com

Wedbush Has Positive Estimate for PTGX Q3 Earnings

August 11 at 2:43 AM | marketbeat.com

Wedbush Expects Higher Earnings for Protagonist Therapeutics

August 9 at 11:44 AM | marketbeat.com

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8, 2025 | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8, 2025 | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7, 2025 | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7, 2025 | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

Jupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

GSA Capital Partners LLP Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Envestnet Asset Management Inc.

August 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 1, 2025 | marketbeat.com

Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Royce & Associates LP Makes New $593,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

July 30, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $570,533.70 in Stock

July 29, 2025 | marketbeat.com

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 10,415 Shares of Stock

July 29, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, PTGX, AAPG, and HCM Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$40.20 +0.16 (+0.40%)

As of 11:08 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

HUTCHMED NASDAQ:HCM

$15.44 -0.04 (-0.23%)

As of 03:16 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Nurix Therapeutics NASDAQ:NRIX

$9.80 +0.15 (+1.55%)

As of 03:18 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Protagonist Therapeutics NASDAQ:PTGX

$54.38 +0.63 (+1.16%)

As of 03:18 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time